First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma
The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2025-01-01
|
| Col·lecció: | Current Oncology |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1718-7729/32/2/68 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
